Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Gilead sciences, inc. save search
Global Precision Cancer Therapeutics Market Report 2022: Overview of Disease Epidemiology, Leading Product sales, Market Estimates and Forecasts, and Competitive Summary of Leading Providers
Published: 2022-12-30 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: -0.74%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: -0.25%
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: -0.08%
H: 0.21%
C: -0.1%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.01%
H: 0.08%
C: -0.95%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.04%
H: 0.16%
C: -0.47%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.04%
H: 0.21%
C: -0.25%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: 0.61%
EXEL | $23.71 1.8% 1.73% 1.6M
|
Health Technology
|
| O: -0.32%
H: 2.91%
C: 2.75%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.46%
H: 0.38%
C: 0.01%
global disease report therapeutics cancer market
Hagens Berman Sobol Shapiro LLP, Hilliard & Shadowen LLP, and Durie Tangri LLP Announce a Class Action Involving Antiretroviral Drugs
Published: 2022-12-28 (Crawled : 21:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.5%
H: 0.42%
C: 0.01%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.43%
H: 0.47%
C: -0.28%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.4%
H: 0.78%
C: 0.41%
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Published: 2022-12-27 (Crawled : 22:00) - globenewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.46%
H: 0.5%
C: -0.97%
gs-1811 immunotherapy potential
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
| Email alert
Add to watchlist
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
| Email alert
Add to watchlist
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $42.98 0.0% 7.4M
|
Health Services
| Email alert
Add to watchlist
ICLR | News | $309.44 0.98% 0.76% 960K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Published: 2022-12-22 (Crawled : 18:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.03%
H: 0.26%
C: 0.04%
sunlenca treatment fda hiv approval living
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -3.21%
H: 1.93%
C: 1.35%
acquire t-cell therapeutics therapy cancer
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
Published: 2022-12-14 (Crawled : 12:00) - ir.voyagertherapeutics.com
VYGR | News | $7.57 -1.05% -1.06% 310K
|
Health Technology
|
| O: -0.16%
H: 1.76%
C: -6.41%
PGEN | $1.42 1.43% 1.41% 570K
|
Health Technology
|
| O: 1.82%
H: 2.98%
C: 1.79%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.85%
H: 1.47%
C: 0.45%
CDNA | $7.98 -3.04% -2.94% 760K
|
Health Technology
|
| O: 0.32%
H: 4.12%
C: 1.9%
therapeutics
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.14%
H: 0.81%
C: 0.79%
yescarta ongoing lymphomas t-cell therapy
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Published: 2022-12-09 (Crawled : 16:00) - biospace.com/
ACLX | $52.82 -2.98% -3.12% 310K
|
|
| O: 20.66%
H: 9.21%
C: 7.11%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
ACLX | $52.82 -2.98% -3.12% 310K
|
|
| O: 20.66%
H: 9.21%
C: 7.11%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration leukemia acute myeloid leukemia
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
SXT | $70.03 0.2% 0.0% 1.3M
|
Distribution Services
|
| O: -0.42%
H: 0.97%
C: -0.33%
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
TRIB | $1.83 -3.87% 11K
|
Health Technology
|
| O: -1.56%
H: 1.58%
C: -1.75%
REPL | $6.33 -1.4% -1.58% 630K
|
Health Technology
|
| O: -0.25%
H: 5.25%
C: 4.17%
MYGN | $18.63 0.16% 0.05% 480K
|
Health Technology
|
| O: -0.67%
H: 1.39%
C: -2.69%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
BNTX | News | $88.09 -0.45% -0.35% 230K
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
APM | $5.56 1.09% 3.34% 16K
|
Health Technology
|
| O: -16.14%
H: 19.24%
C: 14.67%
risk breast genetic cancer study
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 1.82%
H: 1.52%
C: -7.91%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.09%
H: 1.98%
C: 1.82%
medical trial therapeutics phase 1
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
Published: 2022-12-07 (Crawled : 22:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.27%
yescarta japan t-cell agreement therapy
Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors
Published: 2022-11-29 (Crawled : 15:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.34%
H: 0.43%
C: 0.3%
commercialization therapeutics
Gilead Sciences to Present at Upcoming Investor Conferences - November 15, 2022
Published: 2022-11-15 (Crawled : 01:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.34%
H: 0.61%
C: -0.16%
sciences
Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology
Published: 2022-11-15 (Crawled : 21:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.34%
H: 0.61%
C: -0.16%
award sciences drug life technology innovation platform
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Published: 2022-11-11 (Crawled : 12:20) - globenewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -1.44%
H: 0.7%
C: 0.5%
GLPG | News | $28.77 -2.31% -2.33% 130K
|
Health Technology
|
| O: -0.55%
H: 1.8%
C: 1.41%
jyseleca chmp review
Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 6.22%
H: 3.13%
C: -0.56%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 2.59%
H: 0.72%
C: 0.63%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 1.22%
H: 0.01%
C: -1.7%
IOVA 4 | $11.71 -1.27% -1.45% 2.9M
|
Health Technology
|
| O: 6.12%
H: 4.99%
C: 4.21%
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 5.5%
H: 4.35%
C: 3.48%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 1.43%
H: 0.36%
C: -1.08%
ATRA | $0.7147 -0.54% -1.2% 640K
|
Health Technology
|
| O: 2.58%
H: 23.12%
C: 20.85%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: 7.08%
H: 0.84%
C: -0.43%
ADAP | $1.08 -5.26% -5.07% 790K
|
Health Technology
|
| O: 0.0%
H: 7.14%
C: 5.71%
covid-19 research global immunotherapy report impact technology market
Pediatric Health Market Research Report by Type, Therapeutics, Treatment, Treatment Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-03 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: -1.02%
H: 2.67%
C: 0.18%
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 2.28%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
|
| O: 0.83%
H: 1.33%
C: -0.51%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 1.13%
H: 0.63%
C: 0.53%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.18%
C: -2.13%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.42%
H: 0.59%
C: -0.04%
ABT | News | $106.89 -0.65% -0.09% 4.2M
|
Health Technology
|
| O: 1.43%
H: 0.41%
C: 0.25%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.4%
H: 2.75%
C: 1.52%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: 0.72%
H: 1.29%
C: 1.04%
covid-19 treatment research global report impact health market
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.